Surveillance for ototoxicity in platinum-based chemotherapy using mHealth audiometry with extended high-frequencies

Katerina Ehlert, Barbara Heinze, Marien A. Graham, Dewet Swanepoel

Research output: Contribution to journalArticlepeer-review


Objective: This study investigated mHealth enabled surveillance in ototoxicity. Method: A longitudinal study of thirty-two participants receiving chemotherapy participated in the study. Baseline and exit audiograms that included conventional and extended high frequency audiometry were recorded within the patient s treatment venue using a validated mHealth audiometer. Results: Average hearing thresholds at baseline was within the normal range (81.2% left; 93.8% right) reducing at exit testing (71.9% left; 78.1% right). Half of participants presented with a threshold shift according to ototoxicity monitoring criteria. Frequencies affected most were between 4000- and 16000Hz, with left ears significantly more affected than right ears. Noise levels exceeded the maximum permissible ambient noise levels in up to 43.8% of low frequencies (250 - 1000 Hz). Conclusion mHealth-supported audiometry proved to be an efficacious tool for ototoxicity monitoring at the treatment venue. Changes in hearing ability over time could be tracked, improving surveillance in patients with full treatment schedules.

Original languageEnglish
JournalJournal of Laryngology and Otology
Publication statusAccepted/In press - 2022
Externally publishedYes


  • Carboplatin
  • Cisplatin
  • Mhealth surveillance
  • Monitoring
  • Ototoxicity
  • Oxaliplatin
  • Platinum chemotherapy


Dive into the research topics of 'Surveillance for ototoxicity in platinum-based chemotherapy using mHealth audiometry with extended high-frequencies'. Together they form a unique fingerprint.

Cite this